Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic SyndromesBusiness Wire • 10/18/21
Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of HematologyBusiness Wire • 10/11/21
Geron Corporation (GERN) CEO Dr. John Scarlett on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/16/21
Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023Business Wire • 08/16/21
Do Options Traders Know Something About Geron (GERN) Stock We Don't?Zacks Investment Research • 06/21/21
Geron Stock Trading Is Higher On Reinforcing Imetelstat's Approach For Myelofibrosis Treatment, With Data Publication In JournalBenzinga • 06/18/21
Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical OncologyBusiness Wire • 06/17/21
Geron Reports Two Presentations at Virtual European Hematology Association Annual CongressBusiness Wire • 06/14/21
Geron Announces Two Presentations at Upcoming European Hematology Association Annual CongressBusiness Wire • 05/12/21
Geron Corporation (GERN) CEO John Scarlett on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Geron Corporation Reports First Quarter 2021 Financial Results and Recent HighlightsBusiness Wire • 05/10/21
SHAREHOLDER ALERT: Geron Corporation (GERN) Officers and Directors Under Investigation for False Statements and Insider TradingPRNewsWire • 04/19/21